Press Releases - Cardiol Therapeutics

Investor Resources

Contact Us

Investor ResourcesPress Releases

Press Releases

Press Release Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx™ for the Treatment of Acute MyocarditisSeptember 19, 2023

Press Release Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth ConferenceAugust 9, 2023

Press Release Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital MarketAugust 8, 2023

Press Release Cardiol Therapeutics Reports Results of 2023 Annual General MeetingJune 29, 2023

Press Release Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDTJune 27, 2023

Press Release Cardiol Therapeutics Announces Year-End 2022 Update on OperationsMarch 29, 2023

Press Release Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart FailureMarch 7, 2023

Press Release Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent PericarditisJanuary 17, 2023

Press Release Cardiol Therapeutics Commences Multi-center Phase II Pilot Study of CardiolRx™ for the Treatment of Recurrent PericarditisDecember 12, 2022